You are now leaving www.semglee.com, a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.
Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party's terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.
SEMGLEE® is a long-acting insulin that works like Lantus®.1 What sets it apart is the company behind it.
BIOCON BIOLOGICS WILL NEVER STOP
FIGHTING FOR PATIENTS LIKE YOU
DRIVING DOWN THE COST OF INSULIN
by making more affordable options available to patients2
EXPANDING ACCESS TO MORE PEOPLE
with an FDA-approved insulin that can be safely substituted for Lantus3
DELIVERING MORE AROUND THE WORLD
supplying 5.25 billion doses of insulin to patients globally since 20044
SEMGLEE IS AN INSULIN YOU CAN
USE WITH CONFIDENCE
It works like Lantus1-3
It's as effective as Lantus1-3
It's as safe as Lantus1-3
NO CLINICALLY
MEANINGFUL DIFFERENCES
SEMGLEE is an interchangeable biosimilar and you can expect the same familiar experience you've had with Lantus.1,3,5
What's a biosimilar?
SEMGLEE is an FDA-approved biosimilar, or highly similar copy, to the biologic medicine Lantus. Much like a generic drug but more complex in nature.1,3,5
What's an interchangeable biosimilar?
An interchangeable biosimilar is the FDA's designation for a biosimilar that has additional evidence demonstrating that it can be safely substituted for the original biologic medicine at the pharmacy, with the same clinical result expected in any given patient.*5
WE'RE HERE WITH SUPPORT
Pay as little as $0†
- Biocon BiologicsTM offers a savings program for SEMGLEE and Insulin Glargine (insulin glargine-yfgn) injection. These savings cards help eligible patients with commercial health insurance save on out-of-pocket costs
- For questions regarding the savings card program, call 1-800-657-7613 Monday-Friday 8 AM-8 PM ET
We've been there for you
And we've still got your back
Learn more about our global work in insulin here.
References
1. SEMGLEE. Prescribing information. Biocon Biologics Inc; 2023. 2. Joshi SR, Mittra S, Raj P, Suvarna VR, Athalye SN. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know—insulins perspective. Expert Opin Biol Ther. 2023;23(8):693-704. 3. FDA approves first interchangeable biosimilar insulin product for treatment of diabetes. FDA News Release. July 28, 2021. Accessed February 7, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes 4. Biocon Biologics. Strategic Action. Transformational Growth: Integrated Annual Report FY 2023. Biocon Biologics Limited. Accessed March 18, 2024. https://www.biocon.com/docs/BBL_Integrated_Annual_Report_FY2023_Aug08.pdf 5. US Food and Drug Administration. Biosimilar basics for patients. Last updated October 26, 2023. Accessed February 7, 2024. https://www.fda.gov/drugs/biosimilars/biosimilar-basics-patients 6. LANTUS. Prescribing information. sanofi-aventis U.S. LLC; 2023.
IMPORTANT SAFETY INFORMATION
What is SEMGLEE (insulin glargine-yfgn) injection 100 Units/mL?
SEMGLEE is a prescription long-acting man-made insulin used to control high blood sugar in adults and children with diabetes.
- SEMGLEE is not for use to treat diabetic ketoacidosis.
IMPORTANT SAFETY INFORMATION
Do not share your pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Do not use SEMGLEE if you are having an episode of low blood sugar or if you are allergic to insulin glargine products or any of the ingredients in SEMGLEE.
Do NOT reuse needles.
Before using SEMGLEE, tell your healthcare provider about all your medical conditions including if you:
- have liver or kidney problems.
- take other medicines, especially ones called TZDs (thiazolidinediones).
- have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with SEMGLEE.
- are pregnant, planning to become pregnant, or are breastfeeding. It is not known if SEMGLEE may harm your unborn baby or breastfeeding baby.
Tell your healthcare provider about all the medicines you take including prescription and overthe-counter medicines, vitamins, and herbal supplements.
Before you start using SEMGLEE, talk to your healthcare provider about low blood sugar and how to manage it.
Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged. While injecting SEMGLEE, do not press hard, slowly push the injection button to inject the dose. Tell your doctor if you have any new or worsening symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, sudden weight gain.
SEMGLEE should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as SEMGLEE. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.
Do NOT dilute or mix SEMGLEE with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. SEMGLEE must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection.
While using SEMGLEE, do not drive or operate heavy machinery until you know how SEMGLEE affects you. You should not drink alcohol or use other medicines that contain alcohol.
The most common side effect of insulin, including SEMGLEE, is low blood sugar
(hypoglycemia), which may be serious and life threatening.
Signs and symptoms that may indicate low blood sugar include dizziness or
light-headedness, sweating, confusion, headache, blurred vision, slurred speech,
shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.
SEMGLEE may cause serious side effects that can lead to death, such as severe allergic reactions. Get medical help right away if you have: a rash over your whole body, trouble breathing, shortness of breath, a fast heartbeat, sweating, swelling of your face, tongue, or throat, extreme drowsiness, dizziness, or confusion.
Other possible side effects may include swelling, weight gain, low potassium levels, injection site reactions, allergic reactions and skin thickening or pits at the injection site.
Important Safety Information for SEMGLEE (insulin glargine-yfgn) injection pen SEMGLEE pen is a disposable single-patient-use prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.
These are not all the possible side effects of SEMGLEE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
This summary does not include all the information about SEMGLEE and is not meant to take the place of a discussion with your healthcare provider about your treatment.
Please see Full Prescribing Information for SEMGLEE.